Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 169

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 169
---
 Non-            
 Hispanic/Latino |     |            50 |     | Intermediate  |     | VAF < 50%            |     | N/A          |
| 200019095  |     | Newly Diagnosed                  |     | none                 |     |                        63 |     | Female |     | White |     |                 |     |         82.65 |     |               |     |                      |     |              |
| 200013114  |     | Newly Diagnosed                  |     | none                 |     |                        83 |     | Male   |     | White |     |                 |     |          56.8 |     |               |     | NRAS                 |     |              |
| 130800395  |     | Newly Diagnosed                  |     | none                 |     |                        72 |     | Female |     | White |     |                 |     |          75.7 |     | Adverse       |     | TET2, ASXL1, TP53    |     |              |
| 200015280  |     | Newly Diagnosed                  |     | none                 |     |                        67 |     | Female |     | White |     |                 |     |          15.3 |     |               |     | ETV6, BCORL, KRAS    |     |              |
| 200009820  |     | Newly Diagnosed                  |     | none                 |     |                        31 |     | Male   |     | White |     |                 |     |          85.7 |     |               |     | KRAS                 |     |              |
| 200009056  |     | Newly Diagnosed                  |     | none                 |     |                        21 |     | Female |     | White |     |                 |     |          94.8 |     | Adverse       |     | DNMT3A, BCORL1, TP53 |     |              |

<div align='center'>97</div>

AML from bone marrow or PBMC have elevated cell surface TIM-4-L

CER-1236 T cells were also
observed to generate potent anti-cancer responses against myeloid malignancies. AML is a heterogenous, and aggressive hematopoietic malignancy
characterized by the rapid buildup of immature myeloid cells in the bone marrow and blood. We used